Buse, John B. http://orcid.org/0000-0002-9723-3876
Wexler, Deborah J. http://orcid.org/0000-0001-6979-402X
Tsapas, Apostolos http://orcid.org/0000-0003-0221-4072
Rossing, Peter
Mingrone, Geltrude http://orcid.org/0000-0003-2021-528X
Mathieu, Chantal http://orcid.org/0000-0002-6099-2406
D’Alessio, David A.
Davies, Melanie J. http://orcid.org/0000-0002-9987-9371
Article History
First Online: 19 December 2019
Change Date: 15 May 2020
Change Type: Correction
Change Details: The incorrect figure legend was printed for Fig. 2.
Duality of interest
: M.J. Davies reports personal fees and grants from Boehringer Ingelheim, Janssen, Novo Nordisk and Sanofi, and personal fees from AstraZeneca, Eli Lilly, Gilead Sciences Ltd., Intarcia/Servier, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International Inc.
: D. A. D’Alessio reports personal fees from Eli Lilly, Merck, Novo Nordisk and Intarcia, and grants from Merck and Ligand during the conduct of the study; personal fees from Lilly Merck, Novo Nordisk and Intarcia, and grants from Merck and Ligand outside the submitted work.
: C. Mathieu reports grants and fees from Novo Nordisk, grants and fees from Sanofi, grants and fees from Merck Sharp & Dohme, grants and fees from Eli Lilly and Company, grants and fees from Novartis, fees from AstraZeneca, grants and fees from Boehringer Ingelheim, fees from Roche Diagnostics, grants and fees from Medtronic, and grants and fees from ActoBio Therapeutics outside the submitted work, with all fees paid to her university.
: G. Mingrone reports grants and personal fees from Novo Nordisk, personal fees from Johnson & Johnson, personal fees from Fractyl Inc., during the conduct of the study.
: P. Rossing reports grants, non-financial support and other from Novo Nordisk, grants and other from Astra Zeneca, other from Bayer, other from Boehringer Ingelheim, other from MSD, other from Eli Lilly, during the conduct of the study.
: A. Tsapas reports non-financial support from the European Association for the Study of Diabetes, during the conduct of the study; grants and other from Boehringer Ingelheim, grants and other from Novo Nordisk, other from Novartis, grants and other from Sanofi, grants and other from AstraZeneca, grants from GSK, grants and other from European Foundation for the Study of Diabetes (EFSD), outside the submitted work.
: D. J. Wexler reports serving on a Data Monitoring Committee for Novo Nordisk.
: J. B. Buse has provided consultation to Adocia, AstraZeneca, Eli Lilly, MannKind, NovaTarg, Novo Nordisk, Senseonics and vTv Therapeutics with fees paid to the University of North Carolina. He has received grant support from Novo Nordisk, Sanofi and vTv Therapeutics. He is a consultant to Cirius Therapeutics Inc., CSL Behring, Neurimmune AG. He holds stock options in Mellitus Health, PhaseBio, Stability Health and Pendulum Therapeutics. He is supported by a grant from the National Institutes of Health (UL1TR002489).
Free to read: This content has been made available to all.